Impact of hepatitis C status on 20-year mortality of patients with substance use disorders

Anthony J. Accurso*, Darius A. Rastegar, Sharon R. Ghazarian and Michael I. Fingerhood

Abstract

Background: The magnitude of the effect of hepatitis C viral infection on survival is still not fully understood. The objective of this study was to determine whether the presence of hepatitis C viral antibodies in 1991 was associated with increased mortality 20 years later within a cohort of patients with substance use disorders. Secondary objectives were to determine other factors that were associated with increased mortality in the cohort.

Methods: A subset of a 1991 study cohort of patients who had presented for detoxification was reexamined 20 years later. The Social Security Death Index was queried to identify which of the original patients had died. Attributes of survivors and non-survivors were compared, with special attention to their hepatitis C status in 1991. The original study and this analysis were conducted in the chemical detoxification unit at Johns Hopkins Bayview (previously Francis Scott Key Hospital), an academic urban hospital. All participants met the criteria for alcohol or opioid dependence at the time of admission in 1991. The primary study outcome was 20-year mortality after initial admission in 1991, with a planned analysis of hepatitis C status.

Results: Twenty years after admission, 362 patients survived and 82 had died. Of the 284 patients who were hepatitis C positive, 228 survived (80%). Of the 160 patients who were hepatitis C negative, 134 survived (84%). This absolute risk increase of 4% was not statistically significant (p = 0.37). Factors associated with increased mortality included male sex, white race, older age, and reported use of alcohol, cocaine, and illicit methadone. Binary logistic regression including hepatitis C status and these other variables yielded an adjusted odds ratio of 0.87 (95% CI 0.49–1.55); (p = 0.64) for hepatitis C positive 20-year survival.

Conclusions: Hepatitis C positivity was not associated with a statistically significant difference in 20-year survival. The effect of the virus on mortality, if present, is small, relative to the effect of substance use disorders alone.

Keywords: Hepatitis C virus, Chemical dependence, Survival

Background

Hepatitis C has been recognized as the major cause of chronic hepatitis in people who inject drugs since 1992 [1]. Epidemiologic studies have shown the prevalence of hepatitis C infection among drug users to be as high as 85–90% in a variety of cities worldwide [2–4]. Most individuals who test positive for hepatitis C antibody have circulating hepatitis C virus, but 10–15% clear the infection on their own [5]. It is estimated that about 50% of infected individuals progress to chronic liver disease and 20% progress to cirrhosis [6, 7]. The speed of progression appears multi-factorial, with progression accelerated by concurrent HIV infection and heavy alcohol use [8]. Since 1990, the treatment of hepatitis C has depended on the use of injectable interferon as the backbone of treatment [9, 10]. Related to the need for adherence, significant side effects and the intramuscular route of administration, a relatively small percentage of people who inject drugs have been considered for treatment, let

*Correspondence: antaccurso@gmail.com
Johns Hopkins Bayview Medical Center, 5200 Eastern Ave, Mason F. Lord Bldg. West Tower 5th floor, Baltimore, MD 21224, USA

© 2015 Accurso et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
alone treated. However, recent advances in the treatment of hepatitis C have thrust attention to the consideration of treatment for most individuals with hepatitis C viremia [11–15]. This attention is likely to continue to expand as more treatments without interferon are approved over the next few years.

Along with the expanding pharmacotherapy for hepatitis C, there has come the recommendation for expanded screening for hepatitis C [16–21]. The CDC has advocated for universal screening for hepatitis C for all Americans born between 1945 and 1964. This change in the screening guidelines stems from the fact that chronic hepatitis C infection can now be treated by several highly efficacious therapies [22, 23]. An important factor of these new treatment agents is their cost, ranging from 20 to 80 thousand dollars per treatment attempt [24]. Given the high cost of treatment, many third-party payers currently triage their patients based on the extent of liver disease and the likelihood of death from hepatitis C related illness. Knowledge of the natural history of hepatitis C in patients with substance use disorders can aid in the complex decision of who and when to treat. People who inject drugs have a heavy burden of chronic hepatitis C as a population, due to the viral mode of transmission, and are also known to have a higher risk of early mortality than the general population. The relative contribution of chronic hepatitis C infection in this population, compared to the contribution of other dangers such as overdose, suicide and homicide, is still not fully known [25]. Our study offers a prospective examination of this question.

In 1993, an early report on the prevalence of viral hepatitis C among alcohol and drug users showed the correlation of anti-HCV positivity with elevated liver enzymes in that population [1]. The cohort was found to have a hepatitis C antibody prevalence of 63 % overall, and 86 % for those who reported ever using an illicit drug by injection. The arrival of the twenty-year anniversary of this study prompted us to investigate the 20-year all-cause mortality of the cohort, with specific attention to the presence or absence of anti-HCV positivity in 1991. In this study, we look at mortality of a subset of the original cohort, with a focus on whether or not hepatitis C infection was associated with higher mortality.

Methods

The original study was conducted on the Chemical Dependence Unit at Johns Hopkins Bayview Medical Center (then Francis Scott Key Medical Center), in Baltimore, Maryland, between November 1990 and May 1991. Then and now, the unit has 26 inpatient beds and serves a mostly indigent population in the city of Baltimore. Consecutive admissions were entered into the study. All patients met criteria for substance dependence. Demographic data were recorded and patient history related to substance use disorder, HIV infection, hepatitis and sexually transmitted infections was obtained. On admission to the unit, patients had blood testing which included tests for AST, ALT, hepatitis B surface antigen, hepatitis B surface antibody and rapid plasma regain (RPR) test for syphilis. All patients were offered HIV testing. The presence of hepatitis C antibody (anti-HCV) was determined by a first generation enzyme linked immunosorbertent assay (Abbott Laboratories, Abbott Park, Illinois) that detects antibody to the C100-3 antigen. All positive serum samples were retested. Assays for hepatitis B were performed by enzyme immunoassay (Abbott Laboratories). The presence of HIV antibody was determined by an enzyme linked immunosorbertent assay (Genetic Systems, Seattle, Washington) and all positive samples were confirmed by Western blot (Dupont Laboratories, Wilmington, Delaware).

Records from January 1991–May 1991 were located and 444 records were obtained. The Social Security Death Index was accessed to determine whether or not patients had died during the 20 years period since the date of admission. Causes of death were not determined. Prior to proceeding, anti-HCV status was chosen as a variable of interest in the data analysis. An initial bivariate analysis was performed on the mortality groups, using Chi-squared or Fisher’s Exact tests for categorical variables and independent groups t tests for continuous variables, with significance levels set at p < 0.05 using STATA 12.1. Anti-HCV status was then included in a regression analysis with all variables for which the mortality group comparison yielded p values of 0.1 or less. Sex, race, age, history of STD, and histories of alcohol, cocaine and methadone use were found to have p values of 0.1 or less and were therefore included in the analysis. Using SPSS, odds ratios and confidence intervals for each of these variables were obtained. A binary logistic regression was then performed, which generated adjusted odds ratios for each of these variables. Attributes of the anti-HCV positive and anti-HCV negative cohorts were compared, using a Chi squared test in SPSS for categorical variables, and an independent group t test for age. As a final step, a time-to-event plot was created, and the cumulative hazard function was calculated in SPSS, using death dates from the social security death index. This study was approved by the Johns Hopkins Institutional Review Board.

Results

The baseline demographics for the 20-year study cohort are shown in Table 1. There were 288 men and 156 women. The majority were African American (63 %). Of
the 444 patients, 284 (63 %) were anti-HCV positive in 1991. A history of cocaine use and heroin use was correlated with anti-HCV positivity in 1991. These results are described in the initial study and the subgroups of the found-records are presented in Table 1.

The results of the query of the Social Security Death Index are presented in Table 2, which compares the attributes of 20-year survivors to non-survivors. After 20 years, 82 of the 444 study participants were found to be deceased (18 %). The remaining patients were presumed to be alive. The mean ages of 20-year survivors and non-survivors in 1991 were 32.8 and 37.9, respectively (p < 0.001). Male patients had higher mortality than female patients, (23 vs. 10 %, p = 0.001) and white patients in the cohort had greater mortality than black patients (30 vs. 14 %, p < 0.001). Alcohol use (21 vs. 13 %, p = 0.05) and illicit methadone use (31 vs. 17 %, p = 0.04) in 1991 were more weakly associated with death at 20 years. Surprisingly, a history of sexually transmitted disease was more common among survivors.

Hepatitis C antibody status from 1991 was compared between 20-year survivors and non-survivors. Patients who were anti-HCV positive in 1991 had a 20 % mortality, while anti-HCV negative patients had a 16 % mortality. This difference was not statistically significant (p = 0.37), and is illustrated in Fig. 1a. These data are then shown in Fig. 1b in comparison with the expected survivorship of the US general population of the same age, using data from the 1993 CDC death table [26]. Hepatitis B surface antigen positivity and hepatitis B surface antibody positivity were also not associated with mortality differences, but sample sizes may have been too small in some cases to provide adequate power for the comparisons. Liver enzymes were recorded in the initial study in three ranges. Those with lower liver enzymes in 1991 had a slightly greater chance of survival, but this too did not reach statistical significance.

The HCV negative and HCV positive cohorts are compared in Table 3, to look for potential confounding variables. HCV positive patients were more likely to have been male, to have used cocaine and to have used illicit methadone. HCV positive patients were also older, on average, although HCV negative patients had a greater distribution of ages, including the youngest and oldest in the study.

Factors associated with decreased 20-year survival are compared in Table 4, and their unadjusted odds ratios are shown. Results of a binary logistic regression are also included, and displayed as adjusted odds ratios. Male sex and a history of illicit methadone use remain statistically significant after regression analysis. Age also remains significant, with the odds of surviving decreasing slightly but significantly for each year of age of the individual at the start of the study. Again, hepatitis C positivity was not significantly associated with survival (OR 0.75, p = 0.29), and the non-significant association further diminished after binary logistic regression (AOR 0.87, p = 0.64).

In a time to event analysis, the survival curves for HCV positive and HCV negative patients were essentially superimposable. The log rank test performed on the curve confirmed that the difference in the curves was not statistically significant (p = 0.410) (Fig. 2).

Discussion
Our current study was remarkable for two findings. The first was the overall increased mortality rate of this cohort of patients with substance use disorders, as compared to that of the general population. The second finding was the lack of a statistical difference in mortality between those who were HCV positive in 1991, and those who were HCV negative at that time.

A query of the 1993 CDC mortality table shows that about 5000 out of 97,000 people aged 30–35 would...
have been expected to die in 20 years, a death rate of 5.1 % [26]. Our observed death rate in the study population was 18.4 %, indicating that the mortality rate of our cohort of patients with substance use disorders was substantially higher than that of the general US population. Our results are concordant with previous studies showing premature death rates among patients with injection drug use [25]. Of the drugs studied, only illicit methadone use appeared to decrease survival. Cocaine use made hepatitis C positivity more likely, but in concord with prior studies, showed no effect on survival [27]. The presence of the anti-HCV antibody in 1991 did not lead to a statistically significant increase in the 20-year mortality within this cohort. While our study did not have sufficient power to detect a small effect size, ample power was present for moderate or large effect sizes. It is therefore reasonable to conclude that the impact of hepatitis C infection on mortality, if present, was small. This study did not account for morbidity, so it is unknown whether cohort members were living with compensated or decompensated cirrhosis, or experienced other negative effects on their quality of life.

Our comparison of the attributes of the hepatitis C negative and hepatitis C positive cohorts shows that the hepatitis C positive patients were more likely to have been male, to be older, and to have used illicit methadone, three factors which we would expect to make them more likely to die, given the data from this study. These attributes of the hepatitis C positive cohort are probably responsible for the diminished association of HCV positivity and mortality after the regression analysis. The fact that hepatitis C positive patients were more likely to have used cocaine likely made little difference in their survival. The fact that illicit use of methadone was associated with decreased survival may have been incidental but may also be related to the medication’s potential for respiratory depression and cardiac arrhythmias [28, 29]. Hazard from both of these factors may have been increased in patients using methadone outside of a supervised setting [30, 31].

Table 2 Mortality at 20 years, by subgroup

| Demographic | Alive | Deceased | % deceased, % | P   |
|-------------|-------|----------|---------------|-----|
| Totals      | 362   | 82       | 18            |     |
| Age mean, years | 32.8  | 37.9     | <0.0001       |     |
| Gender      |       |          |               |     |
| M           | 222   | 66       | 23            |     |
| F           | 140   | 16       | 10            | 0.001|
| Race*       |       |          |               |     |
| White       | 83    | 35       | 30            |     |
| Black       | 278   | 47       | 14            | 0.001|
| Hx IDU      |       |          |               |     |
| Yes         | 244   | 57       | 19            | 0.72 |
| No          | 118   | 25       | 17            |     |
| Drugs of abuse |       |          |               |     |
| Alcohol     |       |          |               |     |
| Yes         | 237   | 63       | 21            | 0.05 |
| No          | 125   | 19       | 13            |     |
| Cocaine     |       |          |               |     |
| Yes         | 263   | 52       | 17            | 0.1  |
| No          | 99    | 30       | 23            |     |
| Heroin      |       |          |               |     |
| Yes         | 233   | 51       | 18            | 0.71 |
| No          | 129   | 31       | 19            |     |
| Methadone   |       |          |               |     |
| Yes         | 27    | 12       | 31            | 0.04 |
| No          | 335   | 70       | 17            |     |
| Benzodiazepines |      |          |               |     |
| Yes         | 61    | 19       | 24            | 0.18 |
| No          | 301   | 63       | 17            |     |
| Marijuana   |       |          |               |     |
| Yes         | 90    | 20       | 18            | 0.93 |
| No          | 272   | 62       | 19            |     |
| Hx STD      |       |          |               |     |
| Yes         | 152   | 23       | 13            | 0.02 |
| No          | 210   | 59       | 22            |     |
| Hep C Ab    |       |          |               |     |
| Positive    | 228   | 56       | 20            | 0.37 |
| Negative    | 134   | 26       | 16            |     |
| Hep BSAg    |       |          |               |     |
| Positive    | 10    | 4        | 29            | 0.32 |
| Negative    | 352   | 78       | 18            |     |
| HepBSab     |       |          |               |     |
| Positive    | 115   | 27       | 19            | 0.84 |
| Negative    | 247   | 55       | 18            |     |
| HIV         |       |          |               |     |
| Positive    | 23    | 7        | 23            | 0.46 |
| Negative*   | 339   | 74       | 18            |     |
| RPR         |       |          |               |     |
| Positive    | 23    | 29       | 56            | 0.75 |
| Negative    | 339   | 415      | 55            |     |

Table 2 continued

| Demographic | Alive | Deceased | % deceased, % | P   |
|-------------|-------|----------|---------------|-----|
| <31         | 210   | 39       | 16            |     |
| >31 and <60 | 86    | 23       | 21            | 0.21|
| >60         | 66    | 20       | 23            |     |
| ALT         |       |          |               |     |
| <31         | 193   | 39       | 17            |     |
| >31 and <60 | 91    | 23       | 20            | 0.64|
| >60         | 78    | 20       | 20            |     |
Previous studies that have examined the mortality of patients with active hepatitis C virus tend to show little impact on mortality early in the disease course. Grady, et al. found 10-year survivals to be similar between seronegative and seropositive patients for the first 10 years, and suggested divergence around 20 years [33]. Kieland et al. similarly show no change in mortality until three decades out from infection, in patients with an age greater than 50 [35]. Lee et al. documented a substantially greater hepatitis C associated mortality, although their study did not focus specifically on patients with substance use disorders [36]. Grebely et al. show the effect more pronounced only in patients over 50 years of age [33, 34]. Kieland et al. similarly show no change in mortality until three decades out from infection, in patients with an age greater than 50 [35]. Lee et al. documented a substantially greater hepatitis C associated mortality, although their study did not focus specifically on patients with substance use disorders [36]. Our study serves to validate the emerging trend that hepatitis C positivity among patients with substance use disorders does not manifest a mortality difference for at least the first 20 years, and demonstrates this trend within an urban population in the United States.

The impact of hepatitis C virus specifically on patients with substance use disorders was studied by Evans et al. in San Francisco, CA, in a manner very similar to the one that we employed [37]. Similar to our results, they demonstrated that intravenous drug use itself was a risk factor for higher mortality; hepatitis C positivity only showed a non-significant trend towards higher mortality. Larney et al. studied hepatitis C related mortality among veterans with opioid use disorder and found no difference in overall mortality, although hepatitis C patients were more likely to have a liver-related cause of death [38]. In an international study of three large national medical systems, Aspinal et al. document that both drug overdose and all-cause liver mortality were important contributors to mortality among patients with hepatitis C infection [39]. Hayashi et al. did a prospective study of patients with intravenous drug use in Vancouver, and did not find any increased liver mortality in the absence of HIV [40]. Several studies do indicate that HIV/HCV co-infection hastens the progression of liver disease [41–43].

Our study had several limitations. Cause of death was unavailable from the social security death index that we queried. As such, we could not make inferences about the frequency of liver-related mortality. At the time of the study in 1991, HCV RNA tests were not yet commonplace, and as such, there was no way to know which of the anti-HCV positive patients in the cohort had experienced spontaneous clearance. It is reasonable to assume that this would have constituted 10–15% of the group. Another important limitation of this study is the fact that the HIV status of 56% of the sample is unknown. Of those who were tested, 23% were positive for HIV, making it a notable comorbidity within the cohort that could have accounted for some of its increased mortality rate as compared to the general population. Our study was also vulnerable to information bias, as it is possible that some of the cohort-members counted in the anti-HCV negative group may have contracted HCV over the 20 year period of the study. Conversely, some members of the anti-HCV positive group may have obtained HCV treatment. It is
also possible that some of the patients were deceased but not reported to the Social Security administration, but this should not bias the results.

Our study has implications for health policy-related questions. Current medical practice has begun to shift attention toward stewardship and the allocation of medical resources, with campaigns such as Choosing Wisely gaining increased popularity [44]. Given a system with limited financial resources, it may be reasonable to question which therapies would provide the greatest health benefit to patients with substance use disorders. The average cost per treatment episode for outpatient substance use disorder is $2000–7000 [45]. The cost of new oral treatment for hepatitis C infection has been estimated at $84,000 per 12-week course of therapy [24]. Our study suggests that substance use disorders alone increase mortality, a finding that is consistent with prior research [46–48]. It does not, however, support the idea that hepatitis C virus was responsible for a significant fraction of that mortality. Although in a perfect system all patients would be treated for both, our study suggests that younger patients with substance use disorders may derive more mortality benefit from addiction treatment than they would derive from treatment of hepatitis C virus. This effect may shift over time as patients get older. Further research is necessary to establish which

### Table 4 Regression analysis of hepatitis C viral status and factors associated with decreased 20-year survival

| Factor                                      | OR   | CI (P value) | AOR   | CI (P value) |
|---------------------------------------------|------|--------------|-------|--------------|
| Hepatitis C antibody (positive)             | 0.75 | 0.45–1.27 (0.29) | 0.87  | 0.49–1.55 (0.64) |
| Sex (male)                                  | 0.39 | 0.22–0.71 (<0.01) | 0.51  | 0.27–0.95 (0.03) |
| Age                                         | 0.93 | 0.31–0.96 (<0.01) | 0.95  | 0.92–0.98 (<0.01) |
| Race (white)                                | 0.39 | 0.24–0.64 (<0.01) | 0.51  | 0.29–0.89 (0.02) |
| Alcohol use was present                      | 0.58 | 0.33–1.02 (0.06)  | 0.76  | 0.41–1.4 (0.38)  |
| Cocaine use was present                     | 1.47 | 0.88–2.44 (0.14)  | 0.99  | 0.54–1.79 (0.96)  |
| Illicit methadone use was present            | 0.46 | 0.22–0.96 (0.04)  | 0.46  | 0.21–0.99 (0.05)  |
| History of sexually transmitted disease (true) | 1.95 | 1.15–3.33 (0.01)  | 1.70  | 0.95–3.03 (0.07)  |

**Fig. 2 Time to event analysis of mortality for hepatitis C positive and negative patients**
patients would be best served by treatment for one or both conditions.

Conclusions

Hepatitis C antibody positivity was not associated with a statistically significant change in 20 years mortality among a cohort of patients with substance use disorders within an urban setting. The overall mortality of the cohort was higher than that of the general population in both hepatitis C positive and hepatitis C negative patients. The relative effect of hepatitis C status on mortality, if present, is likely quite small in comparison to the effect of substance use disorder within the population studied.

Authors’ contributions

AA is responsible for the majority of the writing and the creation of the tables and figures. MF was the author of the original study, the source of the patient data, and the originator of the study concept. DR gave specific feedback and oversight for data analysis in regard to the regression analysis and the adjusted odds ratios and added greatly with revisions and edits. SG performed the initial statistical analysis. All authors read and approved the final manuscript.

Acknowledgements

All of the authors had full access to all of the data in the study. Anthony Accurso takes responsibility for the integrity of the data and the accuracy of the data analysis.

Competing interests

The authors declare that they have no competing interests.

Financial disclosures

None of the authors have any financial disclosures or conflicts of interest.

Received: 8 March 2015 Accepted: 1 October 2015

Published online: 13 October 2015

References

1. Fingerhood MI. Prevalence of hepatitis C in a chemically dependent population. Arch Intern Med. 1993;153:2025.
2. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore). 1995;74:212–20.
3. Lorrick J, Kral AH, Seal K, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health. 2001;91:46–7.
4. Garfen RS, Doherty MC, Monterosso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18(Suppl 1):S11–9.
5. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450–6.
6. Albert A, Chemello L, Berengnini L. Natural history of hepatitis C virus. J Hepatol. 1999;31(Suppl 1):17–24.
7. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:335–46.
8. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus infected patients. The multicentric Hepatitis 1999;30:1054–8.
9. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321:1506–10.
10. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis interventional therapy group. N Engl J Med. 1989;321:1501–6.
11. Everson GT, Simms KD, Rodriguez-Torres M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014;146:420–9.
12. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370:222–32.
13. Osnami A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310:804–11.
14. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368:45–53.
15. Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med. 2013;369:630–9.
16. Chou R, Cottrell EB, Wason N, Rahman B, Guise JM. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. preventive services task force. Ann Intern Med. 2013;158:101–8.
17. Moyer VA. U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. preventive services task-force recommendation statement. Ann Intern Med. 2013;159:349–57.
18. Ngo-Metzger Q, Ward JW, Valdiserri RO. Expanded hepatitis C virus screening recommendations promote opportunities for care and cure. Ann Intern Med. 2013;159:364–5.
19. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945–1965: recommendations from the centers for disease control and prevention. Ann Intern Med. 2012;157:817–22.
20. [Anonymous]. Summaries for patients: Screening for hepatitis C virus infection in adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2013;159:31–32.
21. [Anonymous]. Summaries for patients. Hepatitis C virus testing of persons born during 1945–1965: Recommendations from the centers for disease control and prevention. Ann Intern Med. 2012;157:38.
22. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.
23. Hezode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2015;64:946–56.
24. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014;59:1246–9.
25. Smyth B, Hoffman V, Fan J, Hser YI. Years of potential life lost among heroin addicts 33 years after treatment. Prev Med. 2007;44:369–74.
26. CDC National Center for Health Statistics. 1993 ABRIDGED LIFE TABLE—TOTAL POPULATION. http://www.cdc.gov/nchs/data/statab/lewk1_93.pdf. Accessed 9 Dec 14.
27. Muhrni PK, Giroer JC. Mortality associated with illegal drug use among adults in the United States. Am J Drug Alcohol Abuse. 2011;37:155–64.
28. Fredheim OMS, et al. Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand. 2008;52:879–89.
29. Krantz MJ. QT interval screening in methadone treatment. Ann Intern Med. 2009;150:387.
30. Bell IR, Butler B, Lawrance A, Batey R, Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009;104:73–7.
31. Ray WA, Chung CP, Murray KT, Cooper WD, Hall K, Steen CM. Out-of-hospital mortality among patients receiving methadone for noncancer pain. JAMA Intern Med. 2015;175:420.
32. Grady D, van den Berg C, van der Helm J, et al. No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion. Clin Gastroenterol Hepatol. 2011;9:786–792(e1).
33. Gibson A, Randall D, Degenhardt L. The increasing mortality burden of liver disease among opioid-dependent people: Cohort study. Addiction. 2011;106:2186–92.
34. Grebely J, Raffa JD, Lai C, et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat. 2011;18:32–41.
35. Kielland KB, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. J Hepatol. 2013;58:31–7.

36. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469–77.

37. Evans JL, Tsui JL, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study. Am J Epidemiol. 2012;175:302–8.

38. Larney S, Bohnert AS, Ganoczy D, et al. Mortality among older adults with opioid use disorders in the veterans health administration, 2000–2011. Drug Alcohol Depend. 2015;147:32–7.

39. Aspinall EJ, Hutchinson SJ, Janjua NZ, et al. Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment. J Hepatol. 2015;62:269–77.

40. Hayashi K, Milloy MJ, Wood E, Dong H, Montaner JS, Kerr T. Predictors of liver-related death among people who inject drugs in vancouver, canada: a 15-year prospective cohort study. J Int AIDS Soc. 2014;17:19296.

41. Fuster D, Cheng DM, Quinn EK, et al. Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. Addiction. 2014;2013(109):62–70.

42. Hernando V, Perez-Cachafeiro S, Lewden C, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol. 2012;57:743–75.

43. Klein MB, Rollet-Kuhfajec KC, Moodie EE, et al. Mortality in HIV-hepatitis C co-infected patients in canada compared to the general canadian population (2003–2013). AIDS. 2014;28:1957–65.

44. Morden NE, Colla CH, Sequist TD, Rosenthal MB. Choosing wisely—the politics and economics of labeling low-value services. N Engl J Med. 2014;370:589–92.

45. French MT, Popovic I, Tapsell L. The economic costs of substance abuse treatment: Updated estimates and cost bands for program assessment and reimbursement. J Subst Abuse Treat. 2008;35:462–9.

46. Hser YL, Hoffman V, Grella CE, Anglin MD. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry. 2001;58:503–8.

47. Joe GW, Simpson DD. Mortality rates among opioid addicts in a longitudinal study. Am J Public Health. 1987;77(3):347–8.

48. Scott CK, Dennis ML, Lauder A, Funk RR, Simeone RS. Surviving drug addiction: the effect of treatment and abstinence on mortality. Am J Public Health. 2011;101:737–44.